跳转至内容
Merck
CN

SML3266

Sigma-Aldrich

AMD070 hydrochloride

≥98% (HPLC)

别名:

(S)-N′-((1H-benzo[d]imidazol-2-yl)methyl)-N′-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine hydrochloride, AMD 070 hydrochloride, AMD 11070 hydrochloride, AMD-070 hydrochloride, AMD-11070 hydrochloride, AMD11070 hydrochloride, Mavorixafor, N′-(1H-Benzimidazol-2-ylmethyl)-N′-(S)-5,6,7,8-tetrahydro-quinolin-8-yl-butane-1,4-diamine hydrochloride, X4P-001 hydrochloride

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C21H27N5 · xHCl
分子量:
349.47 (free base basis)
MDL编号:
UNSPSC代码:
51111800
NACRES:
NA.77

质量水平

方案

≥98% (HPLC)

表单

powder

储存条件

desiccated

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

2-8°C

SMILES字符串

NCCCCN([C@@H]1C2=NC=CC=C2CCC1)CC3=NC4=C(C=CC=C4)N3.Cl

InChI

1S/C21H27N5.ClH/c22-12-3-4-14-26(15-20-24-17-9-1-2-10-18(17)25-20)19-11-5-7-16-8-6-13-23-21(16)19;/h1-2,6,8-10,13,19H,3-5,7,11-12,14-15,22H2,(H,24,25);1H/t19-;/m0./s1

InChI key

DBNMEMJSDAAGNZ-FYZYNONXSA-N

生化/生理作用

AMD070 (AMD11070) is an orally active, reversible and selective CXCR4 (CD184, fusin) antagonist (IC50 = 13 nM against 100 pM 125I-SDF-1α for binding human CD+/CXCR4+ CEM-CCRF cells) that inhibits HIV-1 replication in cultures (IC50/host cells = 2 nM/MT-4 and 26 nM/PBMCs; T-tropic HIV-1NL4.3 strain) with no host cytotoxicity even at concentrations above 23 μM.
Orally active, reversible and selective CXCR4 (CD184, fusin) antagonist that inhibits HIV-1 replication in host cell cultures.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Renato T Skerlj et al.
Journal of medicinal chemistry, 53(8), 3376-3388 (2010-03-20)
The redesign of azamacrocyclic CXCR4 chemokine receptor antagonists resulted in the discovery of novel, small molecule, orally bioavailable compounds that retained T-tropic (CXCR4 using, X4) anti-HIV-1 activity. A structure-activity relationship (SAR) was determined on the basis of the inhibition of
Ju Wang et al.
Translational neurodegeneration, 10(1), 12-12 (2021-04-02)
Currently, there is no cure for Alzheimer's disease (AD). Therapeutics that can modify the early stage of AD are urgently needed. Recent studies have shown that the pathogenesis of AD is closely regulated by an endo/lysosomal asparaginyl endopeptidase (AEP). Inhibition
Guiqin Chen et al.
Science advances, 7(16) (2021-04-18)
Netrin-1, a family member of laminin-related secreted proteins, mediates axon guidance and cell migration during neural development. T835M mutation in netrin receptor UNC5C predisposes to the late-onset Alzheimer's disease (AD) and increases neuronal cell death. However, it remains unclear how

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门